Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CNS Pharmaceuticals, Inc. - Common Stock (NQ:CNSP)

0.8250 -0.0540 (-6.14%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about CNS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement
Via ACCESSWIRE
TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Pricing of Registered Direct, Concurrent Private Placement
Via Investor Brand Network
CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement
Via ACCESSWIRE
Brain Cancer in Kids Could Soon Be Detected by 10-Minute Scan
Via Investor Brand Network
CNS Pharmaceuticals to Present at Alliance Global Partner's 2024 Healthcare Company Showcase
Via ACCESSWIRE
CNS Pharmaceuticals to Present at the LSX World Congress 2024
Via ACCESSWIRE
CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity
Via ACCESSWIRE
BioMedNewsBreaks — CNS Pharmaceuticals Inc.(NASDAQ: CNSP) Enters in Purchase Agreements, Announces Pricing
Via Investor Brand Network
CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement
Via ACCESSWIRE
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Reverse Stock Split
Via Investor Brand Network
Virginia Tech Clinical Trial Seeks End to Brain Cancer Surgery
Via Investor Brand Network
New Research Sheds Light on the Initial Stages of Brain Cancer Development
Via Investor Brand Network
CNS Pharmaceuticals Announces Reverse Stock Split
Via ACCESSWIRE
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at 2024 Healthcare Company Showcase
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Q1 2024 Financial, Business Report
Via Investor Brand Network
CNS Pharmaceuticals Reports First Quarter 2024 Financial Results
Via ACCESSWIRE
New mRNA Vaccine Offers Hope Against Glioblastoma
Via Investor Brand Network
Researchers Seek to Develop Genetically Engineered Brain Cancer Treatment
Via Investor Brand Network
TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at LSX World Congress 2024
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Spotlighted in Upcoming Virtual Investor Lunch Break Event
Via Investor Brand Network
BioMedNewsBreaks — CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Represents Opportunity to Provide Solution for GBM Patients
Via Investor Brand Network
Researchers Link Hormone Treatments to Heightened Risk of Brain Tumors
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases FY 2023 Financial Report, Corporate Update
Via Investor Brand Network
CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements
Via ACCESSWIRE
CNS Pharmaceuticals to Present at Two Investor Conferences in April
Via ACCESSWIRE
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Welcomes Proven Commercialization Leader to Its Board of Directors
Via Investor Brand Network
Study Shows Troops That Sustain Serious Brain Injuries Have Higher Risk of Brain Cancer
Via Investor Brand Network
Scientists Start Trialing First Blood Test Against Brain Cancer
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Information on $4M Public Offering Pricing
Via Investor Brand Network
CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.